Radius Health (RDUS) Misses Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Radius Health Reports Third Quarter 2016 Financial and Operating Results
November 3, 2016 6:30 AM EDTACTIVE Phase 3 trial results published in Journal of American Medical Association and Journal of Bone Mineral Research
Radius to present three abstracts on RAD1901 at San Antonio Breast Cancer Symposium in December
WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Radius or the Company) (Nasdaq: RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, reported its financial results for the third quarter ended September 30, 2016, and provided a business update. As of September 30, 2016, Radius... More
